__NUXT_JSONP__("/drugs/Intetumumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"725735-28-4",chebiId:b,chemicalFormula:b,definition:"A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Intetumumab competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitate the adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases; and propagate signaling events that promote the survival and differentiation of cells in newly formed vasculature.",fdaUniiCode:"GQE1BJE2NI",identifier:"C61070",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C1742","C20401"],synonyms:["CNTO 095","CNTO-95","Human Anti-Alpha-5 Integrin Monoclonal Antibody","Human Monoclonal CNTO 95 gamma1 heavy chain (222-215')-disulfide with Human Monoclonal CNTO 95 kappa light chain dimer (228-228'':231-231'')-bisdisulfide","INTETUMUMAB","Immunoglobulin G1, anti-(human integrin alpha-V (vitronectin receptor subunit alpha or CD51))",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FIntetumumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Intetumumab","","2021-10-30T13:41:16.423Z")));